{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007462","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.936933+00:00","generated_at":"2026-06-02T06:36:37.848418+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HOOKIPA posts Q1 net income of $14.4M; revenue surges to $36.6M on Roche termination","bullets":["Revenue $36.6M (vs $3.2M YoY) mainly from accelerated recognition of Roche upfront and milestone payments.","Net income $14.4M vs net loss $19.7M in Q1 2023; cash $93.0M as of March 31, 2024.","HB-200 Phase 2/3 pivotal trial design aligned with FDA; first patient enrollment expected Q4 2024; PRIME designation from EMA.","HB-700 IND cleared for KRAS-mutated cancers; received $10M milestone from Roche; regained full IP control.","Mark Winderlich appointed Chief Development Officer effective April 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007462","json":"https://secwatch.observer/filing/0001558370-24-007462.json","markdown":"https://secwatch.observer/filing/0001558370-24-007462.md","text":"https://secwatch.observer/filing/0001558370-24-007462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024007462/0001558370-24-007462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024007462/hook-20240509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:36:37.848418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aea56e19247eab0a0d26a35d98fb54cd083fb952","claim":"HOOKIPA Pharma Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million.","evidence_excerpt":"Revenue was $36.6 million for the three months ended March 31, 2024, compared to $3.2 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000155837024007462/0001558370-24-007462-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$36.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}